Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2:83-7.
doi: 10.2147/CPAA.S8863. Epub 2010 Apr 20.

Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

Sayeeda Rahman  1 , Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, Nyi Nyi Naing, Abdul Rashid Abdul Rahman
Affiliations

Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

Sayeeda Rahman et al. Clin Pharmacol. 2010.

Abstract

Introduction: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients.

Methods: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period.

Result: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo.

Discussion and conclusion: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).

Keywords: diabetic vasculopathy; ramipril; rosiglitazone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated marginal means of PWV and AI in type 2 diabetes between treatment with rosiglitazone, ramipril and placebo from base line overtime. With ramipril PWV (P = 0.037) and AI (P = 0.005) and with rosiglitazone AI (P < 0.001) were significantly reduced during overall treatment period from the baseline. Abbreviations: AI, augmentation index; PWV, pulse wave velocity.
See this image and copyright information in PMC

References

    1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434–444. - PubMed
    1. Rahman S, Rahman T, Ismail AA, Rahman ARA. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diab Obes Metab. 2007;9(6):767–780. - PubMed
    1. Shargorodsky S, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hyperten. 2003;16(8):617–622. - PubMed
    1. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In Type 2 diabetes rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27(2):484–490. - PubMed
    1. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes: Results from a controlled randomized study. Circulation. 2005;111(19):2525–2531. - PubMed

Associated data